Description

P21 (P021) 5mg – CNTF-Derived Neurotrophic Research Peptide

P21 (P021) 5mg is an experimental neurotrophic peptide mimetic investigated in scientific research involving neurogenesis, neuronal plasticity, synaptic development and cognitive function. Also known as Peptide 021 or P-21, the compound was developed from a biologically active region of human ciliary neurotrophic factor (CNTF).

P021 contains a modified peptide structure designed to investigate whether selected biological properties associated with CNTF could be reproduced using a smaller molecule. Its structure incorporates an N-terminally acetylated Asp-Gly-Gly-Leu sequence and a modified adamantylated-glycine component at the C-terminus.

Published preclinical studies have examined P021 in animal models of ageing, Alzheimer’s-type pathology, Down syndrome and other neurological conditions. Some studies reported changes in brain-derived neurotrophic factor (BDNF) expression, hippocampal neurogenesis, synaptic markers and behavioural measures of learning and memory.

However, these findings are predominantly from laboratory and animal research. They do not establish that P21 (P021) 5mg safely improves memory, cognition, brain health or neurological disease outcomes in humans.

P21 (P021) 5mg is an investigational research material without an established human therapeutic safety or efficacy profile.

What Is P21 (P021) 5mg?

P21 (P021) 5mg refers to a product labelled as containing 5mg of the experimental neurotrophic compound P021.

P021 was developed through research into ciliary neurotrophic factor, a protein associated with neuronal survival and nervous system biology.

Researchers identified a biologically active region of CNTF and investigated smaller peptide-derived compounds designed to retain selected neurotrophic properties.

The P021 molecule incorporates a four-amino-acid CNTF-derived core together with a modified terminal group containing an adamantane-related structural component.

The compound has been investigated in preclinical studies examining neuronal development, hippocampal neurogenesis and neurological disease models.

Although P021 is frequently described as a nootropic peptide in commercial discussions, it is not an established cognitive-enhancement medicine.

P21 (P021) 5mg Product Specifications

• Product Name: P21 (P021) 5mg
• Scientific Designation: P021
• Alternative Names: P21, P-21, Peptide 021
• Classification: Experimental CNTF-derived neurotrophic peptide mimetic
• Parent Research Molecule: Ciliary neurotrophic factor (CNTF)
• Structural Core: Acetylated Asp-Gly-Gly-Leu
• Research Notation: Ac-DGGL(A)G-NH2
• Structural Modification: C-terminal adamantylated-glycine component
• Reference Molecular Formula: C27H42N6O8
• Reference Molecular Weight: Approximately 578.66 g/mol
• Commonly Listed CAS Number: 1246751-68-7
• PubChem CID: 56599151
• UNII: VV8CZC8PAS
• Labelled Quantity: 5mg
• Research Category: Neuroscience and neurotrophic factor research
• Primary Research Focus: Neurogenesis and neuronal plasticity
• Additional Research Focus: BDNF expression, synaptic biology and cognitive research
• Purity: Requires batch-specific verification
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research only

The chemical specifications above describe the commonly referenced P021 research structure. Commercial preparations may differ in formulation, counterion content and analytical purity. The exact identity and composition of a particular P21 (P021) 5mg batch should be confirmed using appropriate manufacturer documentation.

Understanding the Molecular Structure of P021

P021 is a small synthetic neurotrophic peptide mimetic derived from the CNTF research programme.

Its commonly referenced structural notation is:

Ac-DGGL(A)G-NH2

The notation describes an acetylated Asp-Gly-Gly-Leu peptide core and a modified adamantylated-glycine component.

The adamantane-related modification was introduced to investigate improvements in molecular stability and lipophilicity compared with earlier CNTF-derived peptide fragments.

Importantly, P021 should not be described as an ordinary unmodified six-amino-acid peptide. The terminal component is chemically modified and must be included when identifying the molecule.

Researchers should verify the complete chemical structure, molecular mass and analytical identity of P21 (P021) 5mg.

How Does P21 (P021) Work?

The biological activity of P021 has been investigated primarily in cell culture and animal models.

Published research proposes that P021 may influence neurotrophic signalling pathways associated with neuronal development and synaptic function.

Selected studies reported increased expression of brain-derived neurotrophic factor (BDNF), a protein involved in neuronal survival and synaptic plasticity.

Researchers have also investigated interactions involving leukemia inhibitory factor (LIF) signalling and downstream pathways associated with neuronal development.

These findings suggest that P021 may influence multiple cellular processes in experimental systems.

However, the proposed mechanisms are not fully established across all disease models, and the available evidence does not demonstrate clinical effectiveness in humans.

Scientific Research Into P21 (P021) 5mg

1. P21 (P021) 5mg and Neurogenesis Research

Neurogenesis refers to the formation of new neurons from neural precursor cells.

Adult hippocampal neurogenesis has been investigated extensively in animal models.

P021 was developed as a small CNTF-derived compound intended to influence neurogenic processes.

Selected rodent studies reported changes in neural progenitor cell proliferation and maturation.

However, these findings do not establish that P021 increases neurogenesis in humans.

2. P021 and Hippocampal Research

The hippocampus is a brain structure involved in learning, memory and spatial processing.

Experimental studies have examined P021 in relation to hippocampal neurogenesis and synaptic organisation.

Some rodent studies reported improvements in hippocampal-associated biological markers following P021 exposure.

However, changes in animal hippocampal markers do not demonstrate improved human memory or cognitive function.

3. P21 (P021) 5mg and BDNF Research

Brain-derived neurotrophic factor, abbreviated BDNF, is involved in neuronal survival, development and synaptic plasticity.

Published preclinical studies reported increased BDNF expression following P021 exposure in selected experimental systems.

Researchers have investigated whether changes in BDNF-related signalling contribute to the observed neuronal effects.

However, the results have not been reproduced consistently in every experimental model.

P021 is not chemically identical to BDNF and should not be described as a proven replacement for BDNF.

4. P021 and Leukemia Inhibitory Factor Signalling

Leukemia inhibitory factor, or LIF, is a cytokine involved in cellular development and differentiation.

Earlier CNTF-derived peptide research investigated the role of LIF-related signalling in neuronal precursor cell development.

Selected studies proposed that P021 influences neurogenic processes partly through changes in LIF-associated pathways.

However, the exact molecular interactions remain incompletely characterised.

5. P21 (P021) 5mg and Synaptic Plasticity

Synaptic plasticity refers to the ability of connections between neurons to change in response to activity and experience.

It is important for learning and memory.

P021 has been investigated in animal studies measuring synaptic proteins and structural markers.

Some studies reported changes consistent with improved synaptic organisation in the experimental models examined.

However, these findings do not establish that P021 safely enhances synaptic function in humans.

6. P021 and Dendritic Development

Dendrites are neuronal structures involved in receiving and integrating signals.

Changes in dendritic branching and dendritic spines may influence neuronal communication.

Researchers have investigated P021 in animal models showing abnormalities in dendritic structure.

Selected studies reported improvements in dendritic and synaptic markers.

However, these results remain preclinical.

7. P21 (P021) 5mg and Alzheimer’s Disease Research

Alzheimer’s disease is a complex neurodegenerative disorder associated with cognitive decline and characteristic brain pathology.

P021 has been investigated in transgenic mouse models exhibiting selected Alzheimer’s-related features.

Some studies reported improvements in behavioural measures, synaptic markers and aspects of tau-associated pathology.

However, these animal findings do not establish that P021 prevents, treats or reverses Alzheimer’s disease in humans.

8. P021 and Tau Protein Research

Tau is a neuronal protein involved in stabilising microtubules.

Abnormal tau phosphorylation and aggregation are associated with several neurodegenerative conditions.

Selected P021 animal studies reported changes in tau-related measurements.

Researchers have proposed that these effects may involve BDNF-associated signalling and downstream kinase regulation.

However, the evidence does not establish a clinically validated anti-tau treatment.

9. P21 (P021) 5mg and GSK-3 Beta Research

Glycogen synthase kinase-3 beta, abbreviated GSK-3β, participates in multiple cellular signalling pathways.

It has been investigated in relation to neuronal function and tau phosphorylation.

Some P021 studies reported changes in pathways associated with GSK-3β activity.

These observations contribute to experimental understanding of neurotrophic signalling.

However, the compound’s effects are not established across all neurological models.

10. P021 and Cognitive Behaviour Research

Animal cognition studies use behavioural tasks to investigate learning, memory and related processes.

P021 has been evaluated in rodent models using such tasks.

Selected studies reported improved performance in particular experimental conditions.

However, animal behavioural improvements cannot be translated directly into claims of enhanced human intelligence, memory or concentration.

11. P21 (P021) 5mg and Ageing Research

Ageing can be associated with changes in neuronal plasticity and cognitive function.

Researchers have investigated whether CNTF-derived peptide mimetics influence age-associated changes in animal models.

Some P021 studies reported changes in neurogenic and behavioural measurements in ageing rodents.

However, these findings do not establish anti-ageing effectiveness in humans.

12. P021 and Down Syndrome Research

Down syndrome is associated with characteristic developmental and neurological features.

P021 has been investigated in mouse models used to study selected aspects of Down syndrome-related brain development.

Some studies reported changes in neurogenic markers and behavioural outcomes.

However, animal findings do not establish an effective treatment for people with Down syndrome.

13. P21 (P021) 5mg and CDKL5 Deficiency Research

CDKL5 deficiency disorder is a rare neurodevelopmental condition associated with neurological impairment.

A 2024 study investigated P021 in cellular and mouse models of CDKL5 deficiency.

The researchers reported promising effects in certain cellular experiments but more limited benefits in the animal model.

These mixed findings illustrate why results from one experimental system cannot be assumed to apply universally.

14. P021 and Peptide Stability Research

Peptide stability can influence the reproducibility of experimental research.

The adamantane-related modification in P021 was introduced to investigate improved stability and lipophilicity.

Published preclinical research has examined stability in simulated gastrointestinal conditions.

However, these findings do not establish human oral bioavailability, an approved administration route or a reliable human half-life.

15. P21 (P021) 5mg and Research Reproducibility

Reliable neuroscience research requires accurately identified experimental materials.

P021 is sometimes confused with other CNTF-derived peptides or the unrelated p21 cell-cycle protein.

Researchers should verify the exact modified chemical structure rather than relying on the abbreviated product name alone.

Differences in purity, formulation, chemical identity and storage conditions may influence experimental results.

P21 (P021) 5mg vs Ciliary Neurotrophic Factor

P021 and full-length CNTF are different molecular entities.

CNTF is a protein involved in neurotrophic signalling.

P021 is a much smaller synthetic peptide-derived compound developed from research involving a biologically active CNTF region.

The smaller structure was designed to investigate selected neurotrophic effects while changing molecular properties.

However, P021 does not reproduce every biological function of full-length CNTF.

P21 (P021) 5mg vs Peptide 6

P021 and Peptide 6, also known as P6, belong to the same broader CNTF-derived research lineage.

Peptide 6 is an earlier 11-amino-acid peptide.

P021 was developed from a shorter peptide core with an additional adamantane-related modification.

Although the compounds are related, they have different chemical structures.

Research findings involving Peptide 6 should not automatically be attributed to P021.

P21 (P021) 5mg vs the p21 Protein

The abbreviation P21 can also refer to the p21 cell-cycle regulatory protein, encoded by the CDKN1A gene.

That protein is involved in cell-cycle regulation and other cellular processes.

The neurotrophic research compound P021 is chemically and biologically distinct from the p21 cell-cycle protein.

Researchers should use the full designation P021 when precise identification is necessary.

P21 (P021) 5mg and Cognitive Enhancement Claims

P021 is sometimes described online as a nootropic peptide.

However, the scientific evidence is predominantly preclinical.

There is insufficient reliable human clinical evidence demonstrating that P021 safely improves memory, attention, concentration or cognitive performance.

It should not be marketed as a proven cognitive-enhancement treatment.

P21 (P021) 5mg and Neuroprotection Claims

Some animal studies have reported changes in neuronal and synaptic markers associated with neurotrophic activity.

However, these findings do not establish that P021 protects the human brain against injury, ageing or neurodegenerative disease.

Human therapeutic effectiveness and long-term safety remain unestablished.

P21 (P021) 5mg Research Quality and Documentation

Important considerations when evaluating P21 (P021) 5mg include:

• Verification of the P021 chemical identity
• Confirmation of the acetylated Asp-Gly-Gly-Leu core
• Verification of the adamantane-related terminal modification
• Confirmation of the expected molecular formula
• Verification of the expected molecular mass
• Distinction from the earlier Peptide 6 molecule
• Distinction from the unrelated p21 cell-cycle protein
• Batch-specific certificate of analysis
• Appropriate analytical purity testing
• Mass spectrometry or another suitable identity method
• Confirmation of the labelled 5mg quantity
• Assessment of synthesis-related impurities
• Manufacturer and batch traceability
• Documentation of formulation components
• Product-specific storage and stability information
• Clearly stated research-use classification

Storage and Handling of P21 (P021) 5mg

P21 (P021) 5mg should be stored according to verified manufacturer instructions.

Storage requirements depend on the material’s chemical form, formulation, packaging and stability characteristics.

Researchers should not assume that all P021 preparations have identical storage requirements or shelf lives.

Laboratory handling should follow institutional procedures and relevant safety documentation.

P21 (P021) 5mg Safety and Scientific Limitations

P21 (P021) 5mg is an investigational research material without an established human clinical safety profile.

Published evidence is predominantly based on laboratory experiments and animal studies.

Important uncertainties include human pharmacokinetics, long-term toxicity, neurological effects and the consequences of repeated exposure.

Some preclinical studies reported encouraging neurotrophic findings, while other models demonstrated more limited effects.

There is insufficient reliable human clinical evidence demonstrating safe and effective use for cognitive enhancement, Alzheimer’s disease, Down syndrome, CDKL5 deficiency or anti-ageing.

P021 is not an established approved UK medicine for these purposes.

Research-grade material should not be assumed suitable for human administration.

The labelled 5mg quantity is not a human dosing recommendation.

Frequently Asked Questions About P21 (P021) 5mg

What is P21 (P021) 5mg?

P21 (P021) 5mg is a product listing for an experimental CNTF-derived neurotrophic peptide mimetic with a labelled quantity of 5mg.

What is another name for P021?

P021 is also commonly called P21, P-21 or Peptide 021.

What is the molecular formula of P021?

The commonly referenced molecular formula is C27H42N6O8.

What is the molecular weight of P021?

The reference molecular weight is approximately 578.66 g/mol.

What is the CAS number for P021?

The commonly listed CAS number is 1246751-68-7.

What is the P021 peptide sequence?

The compound is commonly represented by the modified structural notation Ac-DGGL(A)G-NH2. The notation includes an adamantylated-glycine component rather than an ordinary unmodified peptide sequence.

Is P021 the same as Peptide 6?

No. P021 and Peptide 6 are related CNTF-derived research compounds with different chemical structures.

Is P021 the same as the p21 protein?

No. P021 is a neurotrophic research compound, while p21 is an unrelated cell-cycle regulatory protein.

Does P021 increase BDNF?

Some preclinical studies reported increased BDNF expression, but these findings have not been consistently reproduced across all experimental models.

Does P021 improve memory?

Selected rodent studies reported improvements in behavioural measures of learning and memory. Human cognitive benefits have not been established.

Does P021 support neurogenesis?

Some animal studies reported changes in neurogenic markers. There is insufficient evidence demonstrating increased neurogenesis in humans.

Is P021 a treatment for Alzheimer’s disease?

No. P021 is not an established approved treatment for Alzheimer’s disease.

Is P021 a nootropic peptide?

P021 is sometimes described as a nootropic research compound, but its cognitive effects in humans remain unproven.

Is P021 approved for human use?

P021 is not an established approved UK medicine for cognitive enhancement or neurological disease.

What does P21 (P021) 5mg mean?

The designation refers to a labelled quantity of 5mg of research material, not a recommended human dose.

P21 (P021) 5mg – Scientific Product Summary

P21 (P021) 5mg is an experimental CNTF-derived neurotrophic peptide mimetic investigated in neuroscience research.

Its commonly referenced chemical structure incorporates an acetylated Asp-Gly-Gly-Leu core and an adamantane-related terminal modification, with a reference molecular weight of approximately 578.66 g/mol.

Published preclinical studies have examined P021 in relation to neurogenesis, BDNF expression, synaptic plasticity, ageing and neurological disease models.

However, the available evidence does not establish human cognitive benefits, clinical effectiveness or long-term safety.

Researchers evaluating P21 (P021) 5mg should verify chemical identity, purity, formulation, labelled quantity and batch-specific analytical documentation.